Arcus Biosciences, Inc. (RCUS) is currently trading at $17.77 with a Wall Street consensus price target of $41.0, implying potential upside of 130.7% over the next 12 months. 12 analysts currently cover RCUS, with a consensus rating of Buy - 85% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $23.0.
RCUS operates in the Healthcare sector with a market capitalisation of $3B. The stock is down 23.7% year-to-date and is currently trading near the lower end of its 52-week range of $17.43 – $31.73.
Other Healthcare stocks with comparable size and valuation.
Upgrade/downgrade history for RCUS, with each firm's 90-day track record across all stocks we track. See full firm rankings →
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →